ORAMED PHARMACEUTICALS INC.
ORMP · XNASCIK 1176309fmd_1FGZEF4H659JXBPA4T1CR2A3GGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 01, 2007 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 1 | – | 2 |
| Cost of revenue | 0 | 0 | (0) | 0 | – | – | – | – | – | 2 |
| Trading and principal transactions revenue | – | – | – | – | – | – | – | 5 | – | – |
| Gross profit | 0 | 2 | 3 | 3 | – | – | – | – | – | 0 |
| Research and development | 8 | 10 | 12 | 14 | 10 | 21 | 28 | 9 | 6 | 6 |
| Operating income | (10) | (11) | (14) | (15) | (12) | (24) | (41) | (16) | (13) | (15) |
| Interest expense | – | – | – | – | – | – | – | 2 | 1 | – |
| Interest and investment income | – | – | – | – | – | – | – | 0 | – | – |
| Other non-operating income (expense) | – | – | – | – | – | – | 3 | 23 | (2) | 89 |
| Income before taxes | (10) | (10) | (13) | (14) | (12) | 23 | (38) | 5 | (16) | 75 |
| Income tax expense | 1 | 0 | – | 0 | – | – | 0 | – | 3 | 11 |
| Net income from continuing operations | (11) | (10) | – | (14) | – | – | 0 | – | (19) | 64 |
| Net income | (11) | (10) | (13) | (14) | (12) | (23) | (37) | 5 | (19) | 64 |
| Net income to common shareholders | – | – | – | – | 12 | 23 | (37) | – | (19) | 63 |